There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Innovation Lab Capabilities

Innovation Lab Services

Innovation Lab Services

In our efforts to provide the right blend of innovation and value to our clients, ACROBiosystems has NEW Lab Services! Our scientists have implemented and mastered numerous assay platforms over the years.

We are delighted to work with MSD to provide educational handouts and brochures to you. They are only one click away! If you don't find what you need below, please also let us know and we will get it for you!

Brochures and handouts list
  1. MSD Alzheimers Research Products

  2. MSD Bioprocess Applications

  3. MSD Bridging Immunogenicity Assays Guideline

  4. MSD Cell Based Assays

  5. MSD Clinical Immunology Applications

  6. MSD Oncology Applications

  7. MSD Technology Platform

  8. MSD Toxicology


Cytokine/chemokine analytical service

ACROBiosystems leverages the Meso Scale Discovery Electrochemiluminescence (MSD-ECL) platform to provide reliable, high quality data for a diverse variety of biological assay needs.

  1. Up to 10 analytes can be processed in the same panel, which is very efficient and cost effective

  2. Large linear range can be 3 to 4+ log

  3. MSD exhibits excellent sensitivity, precision, minimal matrix effect and free drug interaction

Case Study: Analysis of Proinflammatory Cytokines in Mouse Serum
  1. Samples: Mouse Serum

  2. Analytes:

    10 Mouse Cytokines: IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-5, IL-6, KC/GRO, TNF-α

    4 Human Cytokines: FasL, Granzyme B, IFN-γ, IL-1β

Fig.1 Mouse proinflammatory standard curve

Fig.2 Human proinflammatory standard curve

SPR /BLI analytical service

Surface Plasmon Resonance (SPR) technology is the leader and standard in the field of biomolecular interactions. SPR technology can provide unique insights to reveal the interaction between biomolecules, and help scientists understand the function of biomolecules.

To support the drug development, ACROBiosystems provides a range of services, such as antibody screening, antibody characterization, consistency evaluation, etc.

  1. A professional team to develop and optimize the SPR method.

  2. Using the company's protein products, such as Fc receptor proteins, immunological checkpoint proteins, biotin-labeled proteins, etc.

  3. Based on the SPR technical experience and a large amount of experimental data.

Case Study: affinity of anti-BCMA antibodies in SPR
  1. Ligand: Anti-Human BCMA antibodies (Mouse IgG1)

  2. Analytes: Human BCMA, His Tag (Cat. No. BCA-H522y)

Fig.3 Anti-Human BCMA antibodies (Mouse IgG1) captured on CM5 chip via Anti-mouse antibodies surface, can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with different affinity constants as determined in a SPR assay (Biacore T200).

ADA/PK development service

An idiotope is the unique set of antigenic determinants (epitopes) of the variable portion of an antibody. An anti-idiotypic (Anti-ID) antibody binds to the idiotope of another antibody, usually an antibody drug, which makes it a very powerful tool for antibody drug development, especially for immunogenicity and PK/PD analysis.

To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies and ADA/PK services.

Fig.4 Immobilized Adali**mab at 1 µg/ml, add increasing concentrations of Anti-Adali**mab Antibodies (Cat. No. ADB-Y19, 10% human serum) and then add biotinylated Adali**mab at 5 µg/ml. Detection was performed using HRP-conjugated

Fig.5 Detection of Ritu**mab by bridging ELISA in serum. Immobilized Anti-Ritu**mab Antibodies (Cat. No. RIB-Y37) at 2 μg/ml, added increasing concentrations of Ritu**mab (10% human serum) and then added biotinylated Anti-Ritu**mab Antibodies (Cat. No. RIB-BY35) at 1 μg/ml. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/ml.

Antibody screening service

  1. Case Study: Screening Assay of anti-BCMA antibodies

  2. Coating: Human BCMA, His Tag (Cat. No. BCA-H522y)

  3. Sample1: BAFF/APRIL

  4. Sample2: Anti-Human BCMA antibodies (Mouse IgG1)

Fig.6 Different anti-BCMA antibodies have different neutralization ability for BCMA and BAFF.

Fig.7 Different anti-BCMA antibodies have different neutralization ability for BCMA and APRIL.


Meso Scale Discovery (MSD) Technology-----Broad Range Multiplex Detection via Electrochemiluminescence (ECL)

ACROBiosystems offers an array of MSD-based immunoassays with a proven increase in both dynamic range and sensitivity, made possible through electro chemiluminescent labeling. ACROBiosystems utilizes our expertise to accurately access clients’ needs and to guide in the design of assays more sensitive than traditional ELISA.

Learn More About the MSD Platform:

How the Meso Scale Discovery Platform (MSD-ECL) Works?

Using electrochemiluminescently-labeled detection antibodies, the MSD-ECL platform detects excitation near electrodes located in the bottom of each microplate. As electricity is applied to the plate electrodes, the electrochemiluminescent labels are stimulated to emit light. The intensity of those emissions is then converted to a quantitative measurement of the target analytes in cell supernatant, serum, plasma or whole blood.

Is the MSD-ECL platform right for my assay?

The MSD-ECL platform offers great flexibility with stable, non-radioactive, and easily conjugated labels. Because of these factors, this technology can be applied to all types of traditional ELISAs, such as direct, indirect, sandwich or competitive assays at an increased sensitivity level that can detect samples with concentrations as low as 0.1pg/mL.

We have also found MSD assays are optimal for complex matrices as they typically yield low interference from components like serum or plasma. MSD is particularly advantageous in that its bridging formats are not specific for species or antibody subclass.

Examples of samples:
Tissue culture: Quantification of protein in tissue culture supernatant.
Serum/plasma: Serum/plasma kits provide assay-specific components for the quantitative determination of biomarkers in serum and plasma samples.
Whole cell lysate: Detection of biomarkers in whole cell lysates.
Other: Common high-throughput screening and assay development.

Meso Scale Discovery (MSD-ECL) can be applied in our work with biomarker screening, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and CAR-T cytotoxicity.

What are the key benefits of MSD-ECL?

Top Benefits of MSD Assays:

• Ultra-Sensitive • Small Sample Volumes • Multiplexing • Broad Dynamic Range • Low Background • High Throughput

MSD’s proprietary multi-array technology can provide significantly increased sensitivity and dynamic range over standard ELISA with the added benefit of multiplexing. Fast, yet continuous, non-destructive reads produce consistent assay data with low sample volume requirements and minimal reagent consumption. An added benefit of the electrochemiluminescence (ECL) detection technology is that it reduces assay background by separating the excitation mechanism from the signal.

With a broad range of quantitation, assays conducted using MSD technology are cost-effective and exhibit a reduced need for repeats stemming from readings above the ULOQ or below the LLOQ. This means more valid data points from sample sets in a single run than with other similar platforms.

The combination of rapid read times and the ability to perform multiple, simultaneous tests on a single sample increases productivity, conserves sample, and delivers results quickly.

Case Study:

Case 1: Analysis of Proinflammatory Cytokines in Mouse Serum
Samples: Mouse Serum
10 Mouse Cytokines: IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-5, IL-6, KC/GRO, TNF-α
4 Human Cytokines: FasL, Granzyme B, IFN-γ, IL-1β


• Up to 10 analytes can be processed in the same panel, which is very efficient and cost effective
• Large linear range can be 3 to 4+ log
• MSD exhibits excellent sensitivity, precision, minimal matrix effect and free drug interaction

Case 2: PK Assay – Quantitative Analysis of Therapeutic Antibody in Matrix

With the advantage of ultra-sensitivity and low matrix effect, MSD-ECL technology is a perfect tool for PK assays. We can see from the data; the sensitivity is pushed to ~5ng/ml which can satisfy the requirement of the IND.

Detection of Bevaci**mab by MSD-ECL in serum.

Detection of Trastu**mab by MSD-ECL in serum.

Samples and Turnaround

Sample requirements: Serum, plasma and cell culture supernatants are all compatible with the platform.
Sample volume depends on desired analytes amount. (25ul sample per panel)
Turnaround time: As short as 3 business days!
What is provided to the clients: Raw data file and data report.

SpectraMax i3x Multi-Mode Detection Platform


Sensitivity across spectrum with Spectral Fusion™ Illumination
Expanded dynamic range with cooled PMT

Still have questions?

This web search service is supported by Google Inc.